KR930701402A - N- 하이드로 카르빌 -4- 치환된 피페리딘, 이들의 제조 방법 및 이들의 칼슘 차단제로서의 용도 - Google Patents
N- 하이드로 카르빌 -4- 치환된 피페리딘, 이들의 제조 방법 및 이들의 칼슘 차단제로서의 용도Info
- Publication number
- KR930701402A KR930701402A KR1019930700352A KR930700352A KR930701402A KR 930701402 A KR930701402 A KR 930701402A KR 1019930700352 A KR1019930700352 A KR 1019930700352A KR 930700352 A KR930700352 A KR 930700352A KR 930701402 A KR930701402 A KR 930701402A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- formula
- ethyl
- pentylpiperidine
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract 4
- 229910052791 calcium Inorganic materials 0.000 title claims abstract 4
- 239000011575 calcium Substances 0.000 title claims abstract 4
- 150000003053 piperidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 29
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 13
- 125000000217 alkyl group Chemical group 0.000 claims abstract 9
- 150000003839 salts Chemical class 0.000 claims abstract 8
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 claims abstract 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 6
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 6
- 239000001301 oxygen Substances 0.000 claims abstract 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract 5
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 5
- 239000011593 sulfur Substances 0.000 claims abstract 5
- 125000003342 alkenyl group Chemical group 0.000 claims abstract 3
- 125000000304 alkynyl group Chemical group 0.000 claims abstract 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims abstract 2
- 125000003118 aryl group Chemical group 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 2
- 239000001257 hydrogen Substances 0.000 claims abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- -1 3-trifluoromethylphenoxy Chemical group 0.000 claims 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 2
- 238000009825 accumulation Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- BRLQHFASPKUJRZ-UHFFFAOYSA-N 1-(3,3-diphenylpropyl)-4-[2-(4-fluorophenoxy)ethyl]piperidine Chemical compound C1=CC(F)=CC=C1OCCC1CCN(CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 BRLQHFASPKUJRZ-UHFFFAOYSA-N 0.000 claims 1
- NPSIMRQKLBGCPB-UHFFFAOYSA-N 1-(cyclopropylmethyl)-4-[2-(4-fluorophenoxy)ethyl]piperidine Chemical compound C1=CC(F)=CC=C1OCCC1CCN(CC2CC2)CC1 NPSIMRQKLBGCPB-UHFFFAOYSA-N 0.000 claims 1
- QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 claims 1
- MOLFRRAHAFWISG-UHFFFAOYSA-N 1-pentyl-4-(2-phenoxyethyl)piperidine Chemical compound C1CN(CCCCC)CCC1CCOC1=CC=CC=C1 MOLFRRAHAFWISG-UHFFFAOYSA-N 0.000 claims 1
- MIQTYOURELREAP-UHFFFAOYSA-N 1-pentyl-4-[2-(4-phenylmethoxyphenoxy)ethyl]piperidine Chemical compound C1CN(CCCCC)CCC1CCOC(C=C1)=CC=C1OCC1=CC=CC=C1 MIQTYOURELREAP-UHFFFAOYSA-N 0.000 claims 1
- PAFHTPAKEZLRTP-UHFFFAOYSA-N 1-pentyl-4-[2-(4-phenylphenoxy)ethyl]piperidine Chemical compound C1CN(CCCCC)CCC1CCOC1=CC=C(C=2C=CC=CC=2)C=C1 PAFHTPAKEZLRTP-UHFFFAOYSA-N 0.000 claims 1
- HVFHUCQYXQYIIQ-UHFFFAOYSA-N 1-pentyl-4-[2-(4-propan-2-ylphenoxy)ethyl]piperidine Chemical compound C1CN(CCCCC)CCC1CCOC1=CC=C(C(C)C)C=C1 HVFHUCQYXQYIIQ-UHFFFAOYSA-N 0.000 claims 1
- HSZMBUABLBPSCI-UHFFFAOYSA-N 1-pentyl-4-[2-[4-(trifluoromethyl)phenoxy]ethyl]piperidine Chemical compound C1CN(CCCCC)CCC1CCOC1=CC=C(C(F)(F)F)C=C1 HSZMBUABLBPSCI-UHFFFAOYSA-N 0.000 claims 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- YJIKQTZWSDFMCU-UHFFFAOYSA-N 4-[(4-fluorophenyl)methoxy]-1-pentylpiperidine Chemical compound C1CN(CCCCC)CCC1OCC1=CC=C(F)C=C1 YJIKQTZWSDFMCU-UHFFFAOYSA-N 0.000 claims 1
- UXFJXKKKVZRDKK-UHFFFAOYSA-N 4-[2-(1,3-benzodioxol-5-yloxy)ethyl]-1-pentylpiperidine Chemical compound C1CN(CCCCC)CCC1CCOC1=CC=C(OCO2)C2=C1 UXFJXKKKVZRDKK-UHFFFAOYSA-N 0.000 claims 1
- YZBWAGOXUQPJKK-UHFFFAOYSA-N 4-[2-(3,4-dichlorophenoxy)ethyl]-1-pentylpiperidine Chemical compound C1CN(CCCCC)CCC1CCOC1=CC=C(Cl)C(Cl)=C1 YZBWAGOXUQPJKK-UHFFFAOYSA-N 0.000 claims 1
- JIFIHUWEXKUBQY-UHFFFAOYSA-N 4-[2-(3,4-dichlorophenyl)sulfanylethyl]-1-pentylpiperidine Chemical compound C1CN(CCCCC)CCC1CCSC1=CC=C(Cl)C(Cl)=C1 JIFIHUWEXKUBQY-UHFFFAOYSA-N 0.000 claims 1
- ZBGMVMQWKSCJRC-UHFFFAOYSA-N 4-[2-(4-benzylphenoxy)ethyl]-1-pentylpiperidine Chemical compound C1CN(CCCCC)CCC1CCOC(C=C1)=CC=C1CC1=CC=CC=C1 ZBGMVMQWKSCJRC-UHFFFAOYSA-N 0.000 claims 1
- SXHZRTMMWQRVDO-UHFFFAOYSA-N 4-[2-(4-fluorophenoxy)ethyl]-1-heptylpiperidine Chemical compound C1CN(CCCCCCC)CCC1CCOC1=CC=C(F)C=C1 SXHZRTMMWQRVDO-UHFFFAOYSA-N 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- 150000001340 alkali metals Chemical class 0.000 claims 1
- 210000004958 brain cell Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012038 nucleophile Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000002981 blocking agent Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB909017224A GB9017224D0 (en) | 1990-08-06 | 1990-08-06 | Compounds |
| GB9017224.8 | 1990-08-06 | ||
| GB9007757.8 | 1991-04-12 | ||
| GB919107757A GB9107757D0 (en) | 1991-04-12 | 1991-04-12 | Compounds |
| PCT/GB1991/001340 WO1992002502A1 (en) | 1990-08-06 | 1991-08-05 | N-hydrocarbyl-4-substituted piperidines, their preparation and use as calcium blocking agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR930701402A true KR930701402A (ko) | 1993-06-11 |
Family
ID=26297463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019930700352A Withdrawn KR930701402A (ko) | 1990-08-06 | 1991-08-05 | N- 하이드로 카르빌 -4- 치환된 피페리딘, 이들의 제조 방법 및 이들의 칼슘 차단제로서의 용도 |
Country Status (15)
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5109002A (en) * | 1989-09-08 | 1992-04-28 | Du Pont Merck Pharmaceutical Company | Antipsychotic 1-cycloalkylpiperidines |
| ATE182591T1 (de) * | 1991-09-12 | 1999-08-15 | Smithkline Beecham Plc | 5-ht4 rezeptor antagonisten |
| EP0629190A1 (en) * | 1992-01-28 | 1994-12-21 | Smithkline Beecham Plc | Compounds as calcium channel antagonists |
| NO300539B1 (no) | 1992-11-30 | 1997-06-16 | Sankyo Co | alfa,omega-diarylalkanderivater, med terapeutisk aktivitet for behandling og forhindring av sirkulasjonssykdommer og psykoser, og farmasöytiske preparater inneholdende disse derivater |
| GB9226111D0 (en) * | 1992-12-15 | 1993-02-10 | Smithkline Beecham Plc | Madicaments |
| GB9314973D0 (en) * | 1993-07-20 | 1993-09-01 | Smithkline Beecham Plc | Medicaments |
| GB9319534D0 (en) * | 1993-09-22 | 1993-11-10 | Boots Co Plc | Therapeutic agents |
| WO1995024390A1 (en) * | 1994-03-11 | 1995-09-14 | Smithkline Beecham Plc | Novel phenyl(-alkyl/alkoxy)-1-aminoalkyl-substituted piperidines and pyrrolidines as calcium channel antagonists |
| GB9411045D0 (en) * | 1994-06-02 | 1994-07-20 | Smithkline Beecham Plc | Compounds and use |
| GB9411052D0 (en) * | 1994-06-02 | 1994-07-20 | Smithkline Beecham Plc | Medicaments |
| EP0799201B1 (en) * | 1994-12-21 | 2001-09-26 | Neurosearch A/S | Process for the preparation of substituted 4-ethyl-piperidines |
| AUPN037195A0 (en) * | 1995-01-03 | 1995-01-27 | Australian Nuclear Science & Technology Organisation | Piperidine-based sigma receptor ligands |
| US5981539A (en) * | 1995-09-15 | 1999-11-09 | Neurosearch A/S | Piperidine compounds as calcium channel blockers |
| FR2742051B1 (fr) * | 1995-12-06 | 1998-02-06 | Synthelabo | Utilisation de composes ayant une affinite pour le site de liaison du (3h)ifenprodil pour la fabrication de medicaments utiles dans la prevention et le traitement des neuropathies |
| ZA9610745B (en) * | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
| ZA9610741B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
| ZA9610736B (en) * | 1995-12-22 | 1997-06-27 | Warner Lambert Co | 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists |
| ZA9610738B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | Subtype selective nmda receptor ligands and the use thereof |
| US5843983A (en) * | 1996-02-15 | 1998-12-01 | Sankyo Company, Limited | Diphenylethane compounds containing a saturated heterocyclic group, their preparation, and their therapeutic use |
| CA2262686A1 (en) * | 1996-08-12 | 1998-02-19 | Mark E. Fraley | Thrombin inhibitors |
| AU1600599A (en) | 1998-02-27 | 1999-09-15 | Warner-Lambert Company | Heterocyclic substituted aniline calcium channel blockers |
| US6166052A (en) * | 1998-03-11 | 2000-12-26 | Warner-Lambert Company | Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers |
| US6011035A (en) * | 1998-06-30 | 2000-01-04 | Neuromed Technologies Inc. | Calcium channel blockers |
| DE60011755T2 (de) * | 1999-04-07 | 2005-06-30 | The University Of Virginia Patent Foundation | Calciumkanalblocker als antikrebsmittel |
| GB9917406D0 (en) | 1999-07-23 | 1999-09-22 | Smithkline Beecham Plc | Compounds |
| US7294637B2 (en) | 2000-09-11 | 2007-11-13 | Sepracor, Inc. | Method of treating addiction or dependence using a ligand for a monamine receptor or transporter |
| CA2422055A1 (en) | 2000-09-11 | 2002-03-21 | Sepracor, Inc. | Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission) |
| SE0103818D0 (sv) | 2001-11-15 | 2001-11-15 | Astrazeneca Ab | Chemical compounds |
| SE0203828D0 (sv) * | 2002-12-20 | 2002-12-20 | Astrazeneca Ab | Chemical compounds |
| AR042628A1 (es) * | 2002-12-20 | 2005-06-29 | Astrazeneca Ab | Derivados de piperidina como moduladores del receptor ccr5 |
| SE0301369D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Chemical compounds |
| ATE423111T1 (de) | 2003-07-03 | 2009-03-15 | Euro Celtique Sa | 2-pyridin alkyne derivaten und ihre verwendung für die schmerzbehandlung |
| TW200610761A (en) | 2004-04-23 | 2006-04-01 | Astrazeneca Ab | Chemical compounds |
| SE0401656D0 (sv) * | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | Chemical compounds |
| FR2872416B1 (fr) | 2004-07-01 | 2006-09-22 | Oreal | Utilisation de derives de piperidine pour lutter contre les rides |
| ATE532514T1 (de) * | 2005-09-23 | 2011-11-15 | Ms Science Corp | Piperidin- und piperazinderivate |
| NZ570078A (en) * | 2006-01-27 | 2011-10-28 | Ms Science Corp | Piperidine and piperazine derivatives |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4031221A (en) * | 1974-06-17 | 1977-06-21 | American Hoechst Corporation | Method of treating pain and hypertension |
| EP0077427B1 (fr) * | 1981-10-15 | 1985-05-22 | Synthelabo | Dérivés de pipéridine, leur procédé de préparation et leur application en thérapeutique |
| US4546105A (en) * | 1984-09-04 | 1985-10-08 | Hoechst-Roussel Pharmaceuticals Inc. | Pyrrolylaminopiperidines, compositions thereof and methods of use |
| DE3441929A1 (de) * | 1984-11-16 | 1986-05-28 | Basf Ag, 6700 Ludwigshafen | Verfahren zur herstellung von substituierten piperidinen |
| DE3529994A1 (de) * | 1985-08-22 | 1987-02-26 | Hoechst Ag | Indolinonderivate, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und deren verwendung |
| DK623586A (da) * | 1985-12-27 | 1987-06-28 | Eisai Co Ltd | Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne |
| MY104343A (en) * | 1987-11-23 | 1994-03-31 | Janssen Pharmaceutica Nv | Novel pyridizinamine deravatives |
| FR2636946B1 (fr) * | 1988-09-23 | 1990-11-02 | Lipha | ((diarylmethoxy)alcoyl)-1 pyrrolidines et piperidines, procedes de preparation et medicaments les contenant |
| HU207310B (en) * | 1988-12-02 | 1993-03-29 | Pfizer | Process for producing aryl-piperidine derivatives |
-
1991
- 1991-08-02 MX MX9100513A patent/MX9100513A/es unknown
- 1991-08-02 IE IE275991A patent/IE912759A1/en unknown
- 1991-08-04 IL IL99073A patent/IL99073A0/xx unknown
- 1991-08-05 MA MA22529A patent/MA22250A1/fr unknown
- 1991-08-05 CN CN91105945A patent/CN1061963A/zh active Pending
- 1991-08-05 AU AU83271/91A patent/AU8327191A/en not_active Abandoned
- 1991-08-05 PT PT98574A patent/PT98574A/pt not_active Application Discontinuation
- 1991-08-05 TW TW080106121A patent/TW267164B/zh active
- 1991-08-05 NZ NZ239268A patent/NZ239268A/xx unknown
- 1991-08-05 KR KR1019930700352A patent/KR930701402A/ko not_active Withdrawn
- 1991-08-05 EP EP91914558A patent/EP0542846A1/en not_active Withdrawn
- 1991-08-05 CA CA002088491A patent/CA2088491A1/en not_active Abandoned
- 1991-08-05 WO PCT/GB1991/001340 patent/WO1992002502A1/en not_active Application Discontinuation
- 1991-08-05 JP JP3513952A patent/JPH06500093A/ja active Pending
- 1991-08-06 AP APAP/P/1991/000313A patent/AP279A/en active
Also Published As
| Publication number | Publication date |
|---|---|
| MA22250A1 (fr) | 1992-04-01 |
| TW267164B (enrdf_load_stackoverflow) | 1996-01-01 |
| IL99073A0 (en) | 1992-07-15 |
| CN1061963A (zh) | 1992-06-17 |
| NZ239268A (en) | 1994-06-27 |
| WO1992002502A1 (en) | 1992-02-20 |
| MX9100513A (es) | 1992-04-01 |
| JPH06500093A (ja) | 1994-01-06 |
| EP0542846A1 (en) | 1993-05-26 |
| AP9100313A0 (en) | 1991-10-31 |
| CA2088491A1 (en) | 1992-02-07 |
| PT98574A (pt) | 1992-06-30 |
| AP279A (en) | 1993-08-01 |
| IE912759A1 (en) | 1992-02-12 |
| AU8327191A (en) | 1992-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR930701402A (ko) | N- 하이드로 카르빌 -4- 치환된 피페리딘, 이들의 제조 방법 및 이들의 칼슘 차단제로서의 용도 | |
| KR850000462A (ko) | [[비스(아릴)메틸렌]-1-피페리디닐]알킬-피리미딘온의 제조방법 | |
| KR830006174A (ko) | 기관지 항경련성 화합물 제조방법 | |
| AT500684B8 (de) | Verwendung von schwefelhältigen carbonsäuren zur herstellung eines arzneimittels zur bekämpfung von erkrankungen durch retroviren | |
| RU95117068A (ru) | Антигипертриглицеридемическая композиция, способ ее получения, способ лечения или профилактики гипертриглицеридемии, применение соединений | |
| ZA811223B (en) | Indane derivatives | |
| KR900015721A (ko) | 신규 방법 및 화합물들 | |
| NO20002099L (no) | 6,11-bro-erytromycinderivater | |
| KR900004658A (ko) | 이치환 벤질아민, 그의 제조방법, 약제로서의 그의 용도 및 그의 합성 약제 | |
| ATE144508T1 (de) | 5-amino-8-methyl-7-pyrrolidinylchinolin-3- carbonsäurederivat | |
| KR920002539A (ko) | 콜레스테롤 생합성 억제제로서의 신규 피페리딜 에테르 및 티오에테르 | |
| KR960017663A (ko) | 결합 수용체 길항물질 | |
| KR900018027A (ko) | 피페리딘 유도체, 그의 제조 방법, 및 그것을 유효성분으로 함유하는 의약용 조성물 | |
| ATE19773T1 (de) | Nitroaliphatische verbindungen, verfahren zu deren herstellung und deren verwendung. | |
| DE3568440D1 (en) | New (8s)-8-fluoroerythromycin derivatives, the process for the preparation thereof and the pharmaceutical compositions containing them | |
| KR940003953A (ko) | 1. 4-벤조디옥산 유도체 | |
| KR940009179A (ko) | 벤조푸란 유도체, 그의 제조 방법, 그를 함유한 제약조성물 및 그의 의약으로서의 용도 | |
| DE69532625T2 (de) | NK-1 Rezeptor-Antagonisten zur Behandlung von neuronalen Schäden und Schlaganfällen | |
| DE69518706D1 (de) | Verwendung von Diphenylethanderivaten zur Herstellung eines Arzneimittels zur Behandlung von Glaukom | |
| ES2111086T3 (es) | Compuestos triciclicos anfoteros como agentes antihistaminicos y antialergicos. | |
| AU3959893A (en) | N-aryloxy(thio)alkyl-azacycloalkanes useful as calcium channel antagonists | |
| ZA891769B (en) | Heterocyclic compounds | |
| RU98107807A (ru) | Новые гетероциклические соединения | |
| RU94044323A (ru) | Средство ингибирования навязчиво-компульсивных состояний и расстройств потребления | |
| KR900006287A (ko) | 2-[4-(2-피페리디노-에톡시)-벤조일]-벤조산의 측쇄 알킬 에스테르, 이의 제조 방법 및 진경제로서의 이의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19930205 |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |